The success of next-generation androgen receptor (AR) pathway inhibitors, such as
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …

In normal prostate, neuroendocrine (NE) cells are rare and interspersed among the
epithelium. These cells are believed to provide trophic signals to epithelial cell populations …

Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on
increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against …

Androgens regulate biological pathways to promote proliferation, differentiation, and survival
of benign and malignant prostate tissue. Androgen receptor (AR) targeted therapies exploit …

Lineage plasticity has emerged as an important mechanism of treatment resistance in
prostate cancer. Treatment-refractory prostate cancers are increasingly associated with loss …

The cellular signaling pathways of the prostate play a central role in the induction,
maintenance, and progression of prostate cancer (CaP). Neuroendocrine (NE) cells …

Over the past 5 years, the advent of combination therapeutic strategies has substantially
reshaped the clinical management of patients with advanced prostate cancer. However …

Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. Prostate
tumors in different patients manifest significant inter-patient heterogeneity with respect to …

OBJECTIVE Knowledge of the molecular and cellular changes that occur during the
transition of hormone‐naïve to castration‐resistant prostate cancer (CRPC) is increasing …

OBJECTIVES:: This review aims to provide practising clinicians with the most recent
knowledge of the biological nature of prostate cancer (PC) to facilitate investigation of new …